Onward Medical N.V (ONWD) | Financial Analysis & Statements
Onward Medical N.V. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
84.6M
Total Liabilities
29.2M
Shareholders Equity
55.3M
Debt to Equity
0.53
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2025
Onward Medical N.V Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.8M | 229.0K | 68.0K | 104.0K | 0 |
| Cost of Goods Sold | 1.0M | 22.0K | 0 | 14.7M | 12.0M |
| Gross Profit | 2.7M | 207.0K | 68.0K | -14.7M | -12.0M |
| Gross Margin % | 72.5% | 90.4% | 100.0% | -14,122.1% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 12.3M | 13.9M | 13.8M | 13.1M | 7.9M |
| Selling, General & Administrative | 9.8M | 5.7M | 6.3M | 6.5M | 7.8M |
| Other Operating Expenses | 3.0M | 2.1M | 2.8M | 3.9M | 993.0K |
| Total Operating Expenses | 25.1M | 21.6M | 23.0M | 23.5M | 16.7M |
| Operating Income | -40.9M | -34.9M | -35.5M | -32.0M | -28.5M |
| Operating Margin % | -1,082.4% | -15,223.6% | -52,151.5% | -30,796.2% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 580.0K | 791.0K | 972.0K | 62.0K | 1.0K |
| Interest Expense | 2.2M | 2.0M | 1.4M | 1.5M | 5.6M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -41.5M | -35.8M | -36.1M | -33.5M | -34.2M |
| Income Tax | 311.0K | -40.0K | 107.0K | -766.0K | 69.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -41.8M | -35.7M | -36.2M | -32.8M | -34.3M |
| Net Margin % | -1,105.5% | -15,600.4% | -53,207.4% | -31,511.5% | 0.0% |
| Key Metrics | |||||
| EBITDA | -37.9M | -32.9M | -34.0M | -31.3M | -28.3M |
| EPS (Basic) | - | €-0.80 | €-1.20 | €-1.09 | €-3.62 |
| EPS (Diluted) | - | €-0.80 | €-1.20 | €-1.09 | €-3.62 |
| Basic Shares Outstanding | - | 44629000 | 30184000 | 30184000 | 9485000 |
| Diluted Shares Outstanding | - | 44629000 | 30184000 | 30184000 | 9485000 |
Income Statement Trend
Onward Medical N.V Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 68.1M | 60.0M | 29.8M | 41.8M | 89.4M |
| Short-term Investments | - | - | - | 20.0M | - |
| Accounts Receivable | 1.2M | 160.0K | 0 | - | - |
| Inventory | 803.0K | 102.0K | 0 | - | - |
| Other Current Assets | 1.2M | - | 305.0K | 285.0K | 2.2M |
| Total Current Assets | 74.1M | 63.6M | 31.4M | 64.2M | 92.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 168.0K | 0 | 0 | 0 | 2.2M |
| Goodwill | 10.5M | 12.4M | 11.6M | 12.1M | 11.7M |
| Intangible Assets | 7.0M | 8.5M | 8.0M | 8.3M | 8.3M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | -1.0K | - | - | - |
| Total Non-Current Assets | 10.5M | 12.5M | 12.2M | 12.4M | 12.4M |
| Total Assets | 84.6M | 76.1M | 43.6M | 76.6M | 104.8M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 3.1M | 1.3M | 1.4M | 1.9M | 952.0K |
| Short-term Debt | 538.0K | 597.0K | 568.0K | 427.0K | 473.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 11.1M | 9.3M | 6.7M | 8.2M | 5.5M |
| Non-Current Liabilities | |||||
| Long-term Debt | 13.1M | 14.5M | 16.3M | 14.0M | 13.2M |
| Deferred Tax Liabilities | 347.0K | 303.0K | 631.0K | 670.0K | 2.0M |
| Other Non-Current Liabilities | - | - | - | - | 1.0K |
| Total Non-Current Liabilities | 18.1M | 18.8M | 19.0M | 15.7M | 16.6M |
| Total Liabilities | 29.2M | 28.1M | 25.7M | 24.0M | 22.1M |
| Equity | |||||
| Common Stock | 6.7M | 5.4M | 3.6M | 3.6M | 3.6M |
| Retained Earnings | -222.6M | -181.8M | -145.4M | -108.3M | -76.0M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 55.3M | 48.1M | 17.9M | 52.6M | 82.7M |
| Key Metrics | |||||
| Total Debt | 13.7M | 15.1M | 16.9M | 14.4M | 13.7M |
| Working Capital | 63.0M | 54.3M | 24.7M | 56.0M | 86.8M |
Balance Sheet Composition
Onward Medical N.V Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -41.5M | -35.8M | -36.1M | -33.5M | -34.2M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 2.6M | 2.7M | 2.6M | 1.7M | 8.6M |
| Working Capital Changes | -2.9M | -1.9M | 491.0K | 140.0K | -2.4M |
| Operating Cash Flow | -41.0M | -33.9M | -32.2M | -30.1M | -22.3M |
| Investing Activities | |||||
| Capital Expenditures | -432.0K | -150.0K | -422.0K | -386.0K | -91.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | 0 | 0 | -20.0M | 0 |
| Investment Sales | - | 0 | 20.0M | 0 | - |
| Investing Cash Flow | -432.0K | -150.0K | 19.6M | -20.4M | -91.0K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 14.1M | 1.3M | 0 | 30.0M |
| Debt Repayment | 0 | -15.3M | 0 | - | - |
| Financing Cash Flow | 51.2M | 68.9M | 1.3M | 0 | 110.1M |
| Free Cash Flow | -39.5M | -31.9M | -32.7M | -27.1M | -22.2M |
| Net Change in Cash | 9.7M | 34.9M | -11.3M | -50.5M | 87.7M |
Cash Flow Trend
Onward Medical N.V Key Financial Ratios
Valuation Ratios
Forward P/E
-5.77
Price to Book
2.98
Price to Sales
37.76
PEG Ratio
-5.77
Profitability Ratios
Profit Margin
72.51%
Operating Margin
-494.49%
Return on Equity
-80.85%
Return on Assets
-31.80%
Financial Health
Current Ratio
6.67
Debt to Equity
24.70
Beta
0.98
Per Share Data
EPS (TTM)
€-0.90
Book Value per Share
€0.99
Revenue per Share
€0.12
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ONWD | 204.4M | - | 2.98 | -80.85% | 72.51% | 24.70 |
| Argenx SE | 41.4B | 39.84 | 6.59 | 20.15% | 30.50% | 0.64 |
| Hyloris | 152.3M | -23.65 | 5.70 | -21.61% | -71.71% | 6.08 |
| European Medical | 20.7M | 11.14 | 1.72 | 16.43% | 3.46% | 154.89 |
Financial data is updated regularly. All figures are in the company's reporting currency.